• Profile
Close

Identification of novel step‐up regimen of intralesional triamcinolone acetonide in scalp alopecia areata based on a double‐blind randomized controlled trial

Dermatologic Therapy Dec 10, 2020

Rajan MB, Bhardwaj A, Singh S, et al. - In the present study, the researchers sought to compare hair regrowth and local side effects of various concentrations of intralesional triamcinolone acetonide (TA) in scalp alopecia areata (AA) utilizing clinical and dermoscopic parameters. A double‐blind randomized control trial with four treatment groups (10, 5, 2.5 mg/ml TA and normal saline [NS]) was performed between March 2018 and August 2019. It may be better to start with 2.5 mg/mL intralesional TA in limited scalp AA patients based on the clinical benefit and adverse risk assessment from the study. Based on the serial clinical and dermoscopic response, it can be inferred that TA concentration can be increased as a step-up regimen.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay